Takeda hops onto $61M round for CRISPR player synthesizing Cas9 alternatives
Takeda Ventures and OrbiMed have helped pump $61 million into a New York biotech joining the rush to dramatically expand the CRISPR tool kit. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
